Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT 751 in Combination With Pemetrexed Versus Pemetrexed Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00297089 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT00297089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00297089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT 751 in Combination With Pemetrexed Versus Pemetrexed Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2006
Completion date
January 31, 2009
Enrollment
165 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small-cell lung cancer, nsclc